From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
Agent
Mean (%)
95% CI
Adalimumab
58
49–68
Etanercept
52
45–59
Infliximab
80
70–87
Ustekinumab
69
62–75